Similarly, gefitinib and erlotinib prolong survival for patients with non-small cell lung cancer by inhibiting overactive epidermal growth factor receptor caused by activating mutations in EGFR [2, 3]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.